ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Ultimovacs Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines
July 06, 2021Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication of a review of telomerase-based therapeutic cancer vaccines including the Company's universal cancer vaccine, UV1. -
First patient dosed with therapeutic prostate cancer vaccine
February 20, 2021The trial will evaluate the safety, tolerability and immunogenicity of Ultimovacs’ prostate cancer-specific therapeutic TET-based vaccine. -
Ultimovacs Acquires Immuneed's Immunotherapy Unit
August 31, 2018Ultimovacs has acquired the immunotherapy technology business of Immuneed AB for NOK 50 million.
Pharma Sources Insight January 2025
